Screening for fetal and neonatal alloimmune thrombocytopenia: is it possible and what are the potential outcomes?
- 10 September 2017
- journal article
- Published by Wiley in ISBT Science Series
- Vol. 13 (2) , 187-193
- https://doi.org/10.1111/voxs.12379
Abstract
No abstract availableKeywords
Funding Information
- Seventh Framework Programme
This publication has 30 references indexed in Scilit:
- Incidence and Consequences of Neonatal Alloimmune Thrombocytopenia: A Systematic ReviewPediatrics, 2014
- Screening in pregnancy for fetal or neonatal alloimmune thrombocytopenia: systematic reviewBJOG: An International Journal of Obstetrics and Gynaecology, 2010
- T-cell responses associated with neonatal alloimmune thrombocytopenia: isolation of HPA-1a–specific, HLA-DRB3*0101–restricted CD4+ T cellsBlood, 2009
- Thrombocytopenia in the NeonateBlood Reviews, 2008
- A screening and intervention program aimed to reduce mortality and serious morbidity associated with severe neonatal alloimmune thrombocytopeniaBlood, 2007
- Prospective epidemiologic study of the outcome and cost‐effectiveness of antenatal screening to detect neonatal alloimmune thrombocytopenia due to anti‐HPA‐1aTransfusion, 2005
- Fetomaternal alloimmune thrombocytopenia: a literature review and statistical analysisAustralian and New Zealand Journal of Obstetrics and Gynaecology, 2001
- The Natural History of Fetomaternal Alloimmunization to the Platelet-Specific Antigen HPA-1a (PlA1, Zwa) as Determined by Antenatal ScreeningBlood, 1998
- Alloimmunization to Platelet antigen HPA-1a (PIA1) is strongly associated with both HLA-DRB3∗0101 and HLA-DQB1∗0201Human Immunology, 1992
- Determination of platelet antigens and glycoproteins in the human fetusBlood, 1986